Experts react to new study showing substantial net benefits for sponsors that use DCTs.
“There is room for African Americans at the leadership table.”
“DCTs are here to stay, but they won’t replace all traditional clinical trials,” former FDA official says.
“If you don’t diversify, educate, and raise the level of understanding” in the clinical trial workforce, it “makes it that much harder to achieve” your overall diversity goals, expert says.
“Studies show CRCs spend about 25% of their time on data. Free them up from it, and they’ll have more time to enroll more patients and conduct more trials.”